MRC1 and colonic neoplasm: TMZ may be especially effective in MMR-deficient MPG-overexpressing colon cancer cells, concomitantly inducing DNA damage and disrupting metabolism, potentially leading to higher therapeutic efficiency for this subset of CRC patients.